How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

29,105 results for

Primary Tumor Localization

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Primary Tumor Resection in Patients with Incurable Localized or Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis

Primary Tumor Resection in Patients with Incurable Localized or Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis To assess the impact of primary tumor resection (PTR) on survival and morbidity in incurable colorectal cancer.Systematic literature review and meta-analysis to compare PTR versus primary tumor intact (PTI).Seventy-seven studies were included, reporting on 159,991 participants (94,745 PTR; 65,246 PTI). PTR improved overall survival (hazard ratio [HR] 0.59, P (...)  < 0.0001; mean difference [MD] 7.27 months, P < 0.0001), cancer-specific survival (HR 0.47, MD 10.80), and progression-free survival (HR 0.76, MD 1.67). Overall survival remained significantly improved during subgroup analysis of asymptomatic patients (HR 0.69, MD 3.86), elderly patients (HR 0.46, MD 7.71), patients diagnosed after 2000 (HR 0.62, MD 7.29), patients with colon (HR 0.58, MD 6.31) or rectal (HR 0.54, MD 6.88) primary tumor, patients undergoing resection of primary tumor versus non

2019 EvidenceUpdates

2. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy. (PubMed)

Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy. To evaluate the clinical outcome in patients with de novo metastatic nasopharyngeal carcinoma (NPC) treated or not treated with locoregional radiotherapy (LRRT) based on plasma Epstein-Barr virus (EBV) DNA level and tumor response after palliative (...) chemotherapy (PCT).From 2007 to 2016, 502 patients with de novo metastatic NPC were included in this study. All patients were treated with PCT and 315 patients received LRRT. Our primary study endpoint was overall survival (OS).EBV DNA was detected in 461 patients (91.8%) before treatment but was undetectable in 249 patients (49.6%) after PCT. Three hundred and seventeen patients (63.1%) achieved satisfactory response (complete response or partial response) to PCT. Both the post-PCT EBV DNA level and tumor

Full Text available with Trip Pro

2019 BMC Cancer

3. B7-H3 expression in Merkel cell carcinoma-associated endothelial cells correlates with locally aggressive primary tumor features and increased vascular density. (PubMed)

B7-H3 expression in Merkel cell carcinoma-associated endothelial cells correlates with locally aggressive primary tumor features and increased vascular density. Merkel cell carcinoma is an aggressive cutaneous malignancy whose pathogenesis and prognosis are related to the integrity of the host immune system. Despite promising clinical responses to immune checkpoint blockade, response and resistance remain unpredictable, underscoring a critical need to delineate novel prognostic biomarkers (...) ) cell centroids around the CD31+ (X,Y) cell centroids, was used to estimate a co-localization index equivalent to the percentage of CD31-positive cell centroids that overlap with a B7-H3-poisitive cell centroid.Primary and metastatic MCC exhibit a dynamic range of co-localized CD31 and B7-H3 expression. Increasing co-localized expression of B7-H3 with CD31 significantly associated with increased tumor size (p=0.0060), greater depth of invasion (p=0.0110), presence of lymphovascular invasion (p

2019 Clinical Cancer Research

4. Primary Tumor Resection in Patients with Incurable Localized or Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis. (PubMed)

Primary Tumor Resection in Patients with Incurable Localized or Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis. To assess the impact of primary tumor resection (PTR) on survival and morbidity in incurable colorectal cancer.Systematic literature review and meta-analysis to compare PTR versus primary tumor intact (PTI).Seventy-seven studies were included, reporting on 159,991 participants (94,745 PTR; 65,246 PTI). PTR improved overall survival (hazard ratio [HR] 0.59, P (...)  < 0.0001; mean difference [MD] 7.27 months, P < 0.0001), cancer-specific survival (HR 0.47, MD 10.80), and progression-free survival (HR 0.76, MD 1.67). Overall survival remained significantly improved during subgroup analysis of asymptomatic patients (HR 0.69, MD 3.86), elderly patients (HR 0.46, MD 7.71), patients diagnosed after 2000 (HR 0.62, MD 7.29), patients with colon (HR 0.58, MD 6.31) or rectal (HR 0.54, MD 6.88) primary tumor, patients undergoing resection of primary tumor versus non

2019 World Journal of Surgery

5. Comparative effectiveness review of cryoablation for primary treatment of localized prostate cancer

control to improve survival. Controversy: Locally ablative therapies such as cryoablation may have less morbidity compared with other primary treatment options for localized prostate cancer; however, questions remain about the long-term efficacy for local and distant tumor control and survival. Relevant Questions: Does cryoablation provide effective local tumor control and acceptable rates of remission and long-term disease-free survival in patients with primary localized prostate cancer? Does (...) Comparative effectiveness review of cryoablation for primary treatment of localized prostate cancer Comparative effectiveness review of cryoablation for primary treatment of localized prostate cancer Comparative effectiveness review of cryoablation for primary treatment of localized prostate cancer HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA

2018 Health Technology Assessment (HTA) Database.

6. Primary Bone Tumors.

Primary Bone Tumors. American College of Radiology End User License Agreement ACR Appropriateness Criteria is a registered trademark of the American College of Radiology. By accessing the ACR Appropriateness Criteria®, you expressly agree and consent to the terms and conditions as described at: http://www.acr.org/~/media/ACR/Documents/AppCriteria/TermsandConditions.pdf Personal use of material is permitted for research, scientific and/or information purposes only. You may not modify or create (...) derivative works based on American College of Radiology material. No part of any material posted on the American College of Radiology Web site may be copied, downloaded, stored in a retrieval system, or redistributed for any other purpose without the expressed written permission of American College of Radiology. Date of origin: 1995 Last review date: 2013 ACR Appropriateness Criteria ® 1 Primary Bone Tumors American College of Radiology ACR Appropriateness Criteria ® Clinical Condition: Primary Bone

2019 American College of Radiology

7. Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial. (PubMed)

Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial. Numerous trials have examined the prognostic and predictive value of localization of the primary tumor (LPT) in metastastic colorectal cancer, there is limited information about the predictive value of LPT on different maintenance strategies.We analyzed

2018 Clinical colorectal cancer

8. Locally Ablative Radiation Therapy of a Primary Human Small Cell Lung Cancer Tumor Decreases the Number of Spontaneous Metastases in Two Xenograft Models. (PubMed)

Locally Ablative Radiation Therapy of a Primary Human Small Cell Lung Cancer Tumor Decreases the Number of Spontaneous Metastases in Two Xenograft Models. To investigated the influence of radiation therapy (RT), surgery (OP), radio-chemotherapy (RChT), or chemotherapy (ChT) on small cell lung cancer metastases in 2 xenograft models.A total of 1 × 106 human small cell lung cancer cells (OH1, H69) were subcutaneously injected into severe combined immunodeficiency mice to form a local primary (...) tumor node at the lower trunk. Radiation therapy, OP, RChT, or ChT were started after development of palpable tumors. Chemotherapy was given as a single intraperitoneal injection of cisplatin. Radiation therapy was 5 × 10 Gy on the local tumor node. Two additional groups were implemented to assess primary tumors and distant metastases in untreated mice at the beginning (control group A) and at the end of the experiment (control group B). Proapoptotic, antiproliferative, antiangiogenic, and hypoxic

2018 Biology and Physics

9. A comparison of the local immune status between the primary and metastatic tumor in colorectal cancer: a retrospective study. (PubMed)

A comparison of the local immune status between the primary and metastatic tumor in colorectal cancer: a retrospective study. The anticancer immune response has been reported to correlate with cancer progression. Tumor-infiltrating lymphocytes (TILs), which are one of the indicators of host immunity, affect the tumor growth, metastasis and chemoresistance. Both TILs in the primary tumor and those in the metastatic tumor have been reported to be a useful predictor of the survival and therapeutic (...) , the density of CD4+, CD8+ and FOXP3+ TILs in the primary tumor and that in the metastatic tumor were significantly correlated with that in the metastatic tumor. Furthermore, the activation/suppression marker values of the lymphocytes (i.e., such as PD-1, ICOS, Granzyme B and the PD-1/CD8 ratio) in the primary tumor were correlated with values in the metastatic tumor.The local immune status of the primary tumor was revealed to be similar to that of the metastatic tumor. This suggests that the evaluation

Full Text available with Trip Pro

2018 BMC Cancer

10. Investigation of radiomic signatures for local recurrence using primary tumor texture analysis in oropharyngeal head and neck cancer patients (PubMed)

Investigation of radiomic signatures for local recurrence using primary tumor texture analysis in oropharyngeal head and neck cancer patients Radiomics is one such "big data" approach that applies advanced image refining/data characterization algorithms to generate imaging features that can quantitatively classify tumor phenotypes in a non-invasive manner. We hypothesize that certain textural features of oropharyngeal cancer (OPC) primary tumors will have statistically significant correlations (...) to patient outcomes such as local control. Patients from an IRB-approved database dispositioned to (chemo)radiotherapy for locally advanced OPC were included in this retrospective series. Pretreatment contrast CT scans were extracted and radiomics-based analysis of gross tumor volume of the primary disease (GTVp) were performed using imaging biomarker explorer (IBEX) software that runs in Matlab platform. Data set was randomly divided into a training dataset and test and tuning holdback dataset. Machine

Full Text available with Trip Pro

2018 Scientific reports

11. Prognostic significance of primary tumor localization in stage II and III colon cancer (PubMed)

Prognostic significance of primary tumor localization in stage II and III colon cancer To investigate the effects of tumor localization on disease free survival (DFS) and overall survival (OS) in patients with stage II-III colon cancer.This retrospective study included 942 patients with stage II and III colon cancer, which were followed up in our clinics between 1995 and 2017. The tumors from the caecum to splenic flexure were defined as right colon cancer (RCC) and those from splenic flexure (...) to the sigmoid colon as left colon cancer (LCC).The median age of the patients was 58 years (range: 19-94 years). Male patients constituted 54.2%. The rates of RCC and LCC were 48.4% (n = 456) and 51.6% (n = 486), respectively. During the median follow-up of 90 mo (range: 6-252 mo), 14.6% of patients developed recurrence and 9.1% of patients died. In patients with stage II and III disease with or without adjuvant therapy, DFS was similar in terms of primary tumor localization (stage II; P = 0.547 and P

Full Text available with Trip Pro

2018 World journal of gastrointestinal oncology

12. Adding multiparametric MRI to the MSKCC and Partin nomograms for primary prostate cancer: Improving local tumor staging? (PubMed)

Adding multiparametric MRI to the MSKCC and Partin nomograms for primary prostate cancer: Improving local tumor staging? As a single diagnostic modality, multiparametric MRI (mpMRI) has imperfect accuracy to detect locally advanced prostate cancer (T-stages 3-4). In this study we evaluate if combining mpMRI with preoperative nomograms (Memorial Sloan Kettering Cancer Center [MSKCC] and Partin) improves the prediction of locally advanced tumors.Preoperative mpMRI results of 430 robot-assisted (...) radical prostatectomy patients were analyzed. MSKCC and Partin nomogram scores predicting extraprostatic growth were calculated. Logistic regression analysis was performed, combining the nomogram prediction scores with mpMRI results. The diagnostic value of the combined models was evaluated by creating receiver operator characteristics curves and comparing the area under the curve (AUC).mpMRI was a significant predictor of locally advanced disease in addition to both the MSKCC and Partin nomogram

2018 Urologic oncology

13. Comparative effectiveness review of cryoablation for primary treatment of localized prostate cancer

who prefer a less invasive option than prostatectomy or who are not appropriate surgical candidates. Rationale: The goals of the minimally invasive cryoablation treatment for localized prostate cancer are to use focused cryoablation energy to ablate the entire prostate gland or the cancer-containing part of the gland and achieve complete tumor control to improve survival. Controversy: Locally ablative therapies such as cryoablation may have less morbidity compared with other primary treatment (...) options for localized prostate cancer; however, questions remain about the long-term efficacy for local and distant tumor control and survival. Relevant Questions: Does cryoablation provide effective local tumor control and acceptable rates of remission and long-term disease-free survival in patients with primary localized prostate cancer? Does cryoablation provide acceptable outcomes with regard to patient-reported outcomes, including quality of life, urinary function, prostate symptoms, and sexual

2017 Health Technology Assessment (HTA) Database.

14. Ultrasound-guided high-intensity focused ultrasound for primary treatment of localized prostate cancer

. Citation HAYES, Inc.. Ultrasound-guided high-intensity focused ultrasound for primary treatment of localized prostate cancer. Lansdale: HAYES, Inc.. Directory Publication. 2016 Authors' objectives High-intensity focused ultrasound (HIFU) is a minimally invasive (transrectal) treatment that generates heat through sound energy to destroy tumor tissue. Sound waves produced by an ultrasonic transducer mounted on an endorectal probe penetrate the rectal wall and ablate the entire prostate gland or focal (...) . HIFU may also lead to overtreatment of indolent prostate cancers in patients for whom active surveillance would lead to a good outcome. Relevant Questions: Does HIFU provide effective local tumor control and acceptable rates of remission and long-term disease-free survival in patients with localized prostate cancer? Does HIFU provide acceptable outcomes with regard to urinary function, prostate outcomes, and sexual function? How does HIFU compare with other primary treatment options for localized

2017 Health Technology Assessment (HTA) Database.

15. Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) monotherapy of primary localized prostate cancer

Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) monotherapy of primary localized prostate cancer Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) monotherapy of primary localized prostate cancer Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) monotherapy of primary localized prostate cancer HAYES, Inc Record Status This is a bibliographic record (...) of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) monotherapy of primary localized prostate cancer . Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2016 Authors' objectives Prostate cancer is expected to be the most common cancer diagnosed among men in the United States in 2016, comprising nearly

2017 Health Technology Assessment (HTA) Database.

16. Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) boost treatment in primary localized prostate cancer

Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) boost treatment in primary localized prostate cancer Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) boost treatment in primary localized prostate cancer Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) boost treatment in primary localized prostate cancer HAYES, Inc Record Status This is a bibliographic record (...) of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) boost treatment in primary localized prostate cancer . Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2016 Authors' objectives Prostate cancer is expected to be the most common cancer diagnosed among men in the United States in 2016, comprising nearly

2017 Health Technology Assessment (HTA) Database.

17. Positron emission tomography-computed tomography (PET-CT) for detection of primary site in neuroendocrine tumors of unknown origin

misalignment between PET and CT images in order to identify and localize primary tumors. Controversy: PET-CT offers an alternative to other conventional diagnostic modalities for the identification and localization of unknown primary tumors in patients with metastatic NETs. However, a definitive reference standard other than histopathology for detection of unknown primary tumors is lacking, which makes evaluation of PET-CT for this indication challenging. Key Questions Can PET-CT accurately localize (...) Positron emission tomography-computed tomography (PET-CT) for detection of primary site in neuroendocrine tumors of unknown origin Positron emission tomography-computed tomography (PET-CT) for detection of primary site in neuroendocrine tumors of unknown origin Positron emission tomography-computed tomography (PET-CT) for detection of primary site in neuroendocrine tumors of unknown origin HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment from

2018 Health Technology Assessment (HTA) Database.

18. Frequency of and risk factors for tumor upstaging after wide local excision of primary cutaneous melanoma. (PubMed)

Frequency of and risk factors for tumor upstaging after wide local excision of primary cutaneous melanoma. Detecting a more advanced stage of the primary melanoma after wide local excision and reconstruction can complicate patient counseling about prognosis, management of surgical margins, and indications for sentinel lymph node biopsy.To identify the frequency of and risk factors associated with upstaging after wide local excision of primary melanoma.Retrospective, single center, cross (...) -sectional study of 1332 consecutive in situ to stage T4a melanomas treated with wide local excision.The overall rate of upstaging of melanoma was 3.9% (52/1332). After multivariate analysis, the greatest risk factor for upstaging was anatomic location on the head, neck, hands, feet, genitals, or pretibial leg (odds ratio [OR] 7.06, P < .001) followed by extension of the melanoma to the base of the biopsy specimen (OR 3.42, P < .001); the need for multiple preoperative scouting biopsies (OR 1.89, P

2017 Journal of American Academy of Dermatology

19. Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study. (PubMed)

Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study. Therapeutic options to cure advanced, recurrent, and unresectable thymomas are limited. The most important factor for long-term survival of thymoma patients is complete resection (R0) of the tumor. We therefore evaluated the response to and the induction of resectability of primarily or locally recurrent unresectable thymomas and thymic carcinomas (...) , respectively. Octreotide LAR plus prednisone treatment was discontinued in two patients before week 12 due to unsatisfactory therapeutic effects or adverse events. The most frequent adverse events were gastrointestinal (71%), infectious (65%), and hematological (41%) complications. In conclusion, octreotide LAR plus prednisone is efficacious in patients with primary or recurrent unresectable thymoma with respect to tumor regression. Octreotide LAR plus prednisone was well tolerated and adverse events were

Full Text available with Trip Pro

2016 PLoS ONE

20. Is there a different dose-effect relation between the primary tumor and involved lymph nodes in locally advanced non-small-cell lung cancer? A hypothesis-generating study. (PubMed)

Is there a different dose-effect relation between the primary tumor and involved lymph nodes in locally advanced non-small-cell lung cancer? A hypothesis-generating study. It is unknown whether the dose-response relation of the primary tumor in NSCLC is different from that of the involved lymph nodes (LN). As the recurrence rate is much lower in LN, we hypothesized that LN need a lower radiation dose.A retrospective analysis of prospective data was performed on patients with locally advanced (...) in 40% of patients together with a significant dose-response relationship (p = .033). Baseline nodal diameter was not associated with INR (p = .76), while primary tumor diameter was a highly significant predictor for relapse (p = .0031).These results suggest that LN control may be achieved at lower radiation doses than needed for the primary tumor. Prospective dose de-escalation studies on LN are warranted to decrease the incidence of severe esophagitis without compromising local tumor control.

Full Text available with Trip Pro

2017 Acta Oncologica

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>